These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29134432)

  • 1. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
    Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
    Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
    Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F
    J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
    Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
    Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
    Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
    J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
    Soria JC; Smit E; Khayat D; Besse B; Yang X; Hsu CP; Reese D; Wiezorek J; Blackhall F
    J Clin Oncol; 2010 Mar; 28(9):1527-33. PubMed ID: 20159815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
    Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
    Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
    Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study.
    Hsu PC; Chang JW; Wang CC; Wu CT; Lin YC; Wang CL; Lin TY; Li SH; Wu YC; Kuo SC; Yang CT; Liu CY; Chen CH
    Thorac Cancer; 2019 Aug; 10(8):1683-1691. PubMed ID: 31276309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
    Tan EH; Rolski J; Grodzki T; Schneider CP; Gatzemeier U; Zatloukal P; Aitini E; Carteni G; Riska H; Tsai YH; Abratt R
    Ann Oncol; 2009 Jul; 20(7):1249-56. PubMed ID: 19276396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
    Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
    Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.